D. Carbone - Concepedia

Author

D. Carbone

The University of Texas Southwestern Medical Center

Also Known As

Carbone DP, D CARBONE, D P Carbone, D. Carbone, D. P. Carbone, D.P. Carbone, DP Carbone

Publications

691

Citations

H-Index

Concepts

All Affiliations

The University of Texas Southwestern Medical Center The Ohio State University Memorial Sloan Kettering Cancer Center National Cancer Institute

About

D. Carbone is an author at The University of Texas Southwestern Medical Center specializing in medicine, pathology, and cell biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	334
2	Cell Biology	5	5	303
3	Pathology	5	5	126
4	Immunology	4	4	256
5	Health Sciences	1	1	10

D. Carbone

Publications

658

Citations

H-Index

Page 1

	Year	Citations
Induction of cytotoxic T lymphocytes and antitumor immunity with DNA vaccines expressing single T cell epitopes I. Frank Ciernik, Jay A. Berzofsky, D. Carbone The Journal of Immunology	1996	196
A mutant p53 tumor suppressor protein is a target for peptide-induced CD8+ cytotoxic T-cells. Michael Yanuck, D. Carbone, C D Pendleton, PubMed Mutant P53Cancer ImmunosurveillanceMutant P53 GeneOncogenic AgentImmunology	1993	174
Antibodies Against Autologous Tumor Cell Proteins in Patients With Small-Cell Lung Cancer: Association With Improved Survival Sebastian Winter, Yoshitaka Sekido, J D Minna, JNCI Journal of the National Cancer Institute	1993	99
Neural cell adhesion molecule expression and messenger RNA splicing patterns in lung cancer cell lines are correlated with neuroendocrine phenotype and growth morphology. D. Carbone, Aurelia M. C. Koros, R. Ilona Linnoila, PubMed Cell Lines ShareImmunologyPathologyMessenger RnaCancer Biology	1991	56
Polymorphic sites within the MCC and APC loci reveal very frequent loss of heterozygosity in human small cell lung cancer Domenico D’Amico, D. Carbone, BE Johnson, Lung Cancer Tumor BiologyTumor HeterogeneityMedicineGeneticsCancer Genomics	1993	34
Vaping, Smoking and Lung Cancer Risk Marisa A. Bittoni, D. Carbone Journal of Oncology Research and Therapy	2024	29
<i>EGFR</i> and <i>KRAS</i> mutations in patients with bronchioloalveolar carcinoma treated with erlotinib in a phase II multicenter trial Mark G. Kris, Andrew Sandler, V. A. Miller, Journal of Clinical Oncology PathologyTumor BiologyOncologyReceptor Tyrosine KinaseBronchioloalveolar Carcinoma	2005	23
72 Multicenter trial of docetaxel (Taxotere) in platinum-treated non-small cell lung cancer (NSCLC): Confirmation of prolonged survival David R. Gandara, Everett E. Vokes, M. Green, Lung Cancer OncologyMedicineMetronomic TherapyPathologyProlonged Survival	1997	21
Expression of transforming growth factor beta and transforming growth factor beta receptors on AIDS-associated Kaposi's sarcoma. I. Frank Ciernik, B H Krayenbühl Ciernik, Clay J. Cockerell, PubMed T-regulatory CellImmune RegulationImmunologyPathologyImmunologic Mechanism	1995	16
OA13.07 Neoadjuvant Atezolizumab in Resectable NSCLC Patients: Immunophenotyping Results from the Interim Analysis of the Multicenter Trial LCMC3 Filiz Öezkan, Kai He, Dwight H. Owen, Journal of Thoracic Oncology Interim AnalysisOa13.07 Neoadjuvant AtezolizumabMedicineImmunologyClinical Trials	2019	10

Page 1